CNSP CNS Pharmaceuticals, Inc.

Nasdaq cnspharma.com


$ 9.50 $ -0.02 (-0.21 %)    

Wednesday, 15-Oct-2025 15:59:52 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 9.52
$ 9.67
$ 8.50 x 623
$ 9.85 x 19
$ 9.30 - $ 9.76
$ 4.93 - $ 221.94
13,423
na
5.47M
$ 1.62
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-15-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 02-12-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 12-20-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-upgrades-cns-pharma-to-buy-announces-20-price-target

Maxim Group analyst Jason McCarthy upgrades CNS Pharma (NASDAQ:CNSP) from Hold to Buy and announces $20 price target.

 cns-pharmaceuticals-q2-eps-642-beats-960-estimate

CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(6.42) per share which beat the analyst consensus estimate of $...

 cns-pharma-announces-1-for-12-reverse-split-of-its-common-stock

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in t...

 cns-pharmaceuticals-q4-eps-158-beats-600-estimate

CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(1.58) per share which beat the analyst consensus estimate of $...

 cns-pharma-prices-public-offering-of-395m-shares-at-1265shr-issuing-series-f-warrants

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in t...

Core News & Articles
Market-Moving News for May 13th
05/13/2025 11:11:57

COIN: 10% | Coinbase Global shares are trading higher it was announced that the company will join the S&P 500, effective be...

 maxim-group-downgrades-cns-pharma-to-hold

Maxim Group analyst Jason McCarthy downgrades CNS Pharma (NASDAQ:CNSP) from Buy to Hold.

 cns-pharmas-cancer-drug-misses-survival-goal-but-may-offer-fewer-side-effects

CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION